Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells (UT Health Houston)
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
This investigational cell therapy consists of autologous bone marrow mononuclear cells (BM-MNCs) developed by The University of Texas Health Science Center at Houston in collaboration with the Cardiovascular Cell Therapy Research Network (CCTRN). The therapy involves harvesting a patient's own bone marrow, isolating the mononuclear cell fraction—which includes hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells—and delivering them via electromechanical-guided transendocardial injection directly into the ischemic myocardium. The treatment is designed for patients with chronic ischemic heart disease, left ventricular dysfunction, and ischemic cardiomyopathy who are not candidates for standard revascularization. The primary therapeutic goal is to promote neovascularization and improve myocardial perfusion and contractile performance through paracrine signaling and potential direct tissue regeneration.
- Other names
- Adult stem cellsFOCUS-CCTRN cell therapyautologous bone marrow mononuclear cells
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells (UT Health Houston).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells (UT Health Houston).